Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine.

2.50
Hdl Handle:
http://hdl.handle.net/10541/94778
Title:
Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine.
Authors:
Thatcher, Nick; Hopwood, Penelope; Anderson, Heather
Abstract:
Alongside objective response rate, quality of life of patients is important in the treatment of cancer, particularly in the palliative setting. Quality of life is difficult to define precisely and is correspondingly difficult to assess. However, a number of methods have been devised and self-report questionnaires are now widely used. Patients with metastatic non-small cell lung cancer (NSCLC) have a poor prognosis with few patients surviving longer than 8 or 9 months. Curative treatment is often not possible and few patients receive active treatment. Although some patients will accept toxic treatments in return for increased survival, it is generally hoped that any treatment, curative or palliative, will not adversely affect patients' quality of life. In three studies in which gemcitabine was used as a single agent in metastatic NSCLC, objective response rates of 20% were obtained. Gemcitabine was well tolerated. Symptoms improved in the studies where disease-related symptoms were assessed. The degree of improvement compared well with historical data on the relief offered by standard radiotherapy and combination chemotherapy. These findings have led to the initiation of a randomised trial to compare the relief offered by gemcitabine plus best supportive care with best supportive care, using quality of life assessments as a primary endpoint.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.
Citation:
Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. 1997, 33 Suppl 1:S8-13 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Jan-1997
URI:
http://hdl.handle.net/10541/94778
DOI:
10.1016/S0959-8049(96)00336-X
PubMed ID:
9166093
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorHopwood, Penelopeen
dc.contributor.authorAnderson, Heatheren
dc.date.accessioned2010-03-23T17:23:29Z-
dc.date.available2010-03-23T17:23:29Z-
dc.date.issued1997-01-
dc.identifier.citationImproving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. 1997, 33 Suppl 1:S8-13 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid9166093-
dc.identifier.doi10.1016/S0959-8049(96)00336-X-
dc.identifier.urihttp://hdl.handle.net/10541/94778-
dc.description.abstractAlongside objective response rate, quality of life of patients is important in the treatment of cancer, particularly in the palliative setting. Quality of life is difficult to define precisely and is correspondingly difficult to assess. However, a number of methods have been devised and self-report questionnaires are now widely used. Patients with metastatic non-small cell lung cancer (NSCLC) have a poor prognosis with few patients surviving longer than 8 or 9 months. Curative treatment is often not possible and few patients receive active treatment. Although some patients will accept toxic treatments in return for increased survival, it is generally hoped that any treatment, curative or palliative, will not adversely affect patients' quality of life. In three studies in which gemcitabine was used as a single agent in metastatic NSCLC, objective response rates of 20% were obtained. Gemcitabine was well tolerated. Symptoms improved in the studies where disease-related symptoms were assessed. The degree of improvement compared well with historical data on the relief offered by standard radiotherapy and combination chemotherapy. These findings have led to the initiation of a randomised trial to compare the relief offered by gemcitabine plus best supportive care with best supportive care, using quality of life assessments as a primary endpoint.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntimetabolites, Antineoplastic-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshDeoxycytidine-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshQuality of Life-
dc.titleImproving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.